TY  - JOUR
AU  - Berghoff, Anna S
AU  - Wolpert, Fabian
AU  - Holland-Letz, Tim
AU  - Koller, Romina
AU  - Widhalm, Georg
AU  - Gatterbauer, Brigitte
AU  - Dieckmann, Karin
AU  - Birner, Peter
AU  - Bartsch, Rupert
AU  - Zielinski, Christoph C
AU  - Weller, Michael
AU  - Preusser, Matthias
TI  - Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.
JO  - Neuro-Oncology
VL  - 19
IS  - 9
SN  - 1523-5866
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DKFZ-2017-04019
SP  - 1255-1262
PY  - 2017
AB  - We aimed to investigate the potential of standard hematologic and serum biochemical parameters to provide an independent and substantial contribution to the prediction of survival in patients with newly diagnosed brain metastases (BM).Hemoglobin, white blood cell count, platelet count, serum albumin, creatinine, lactate dehydrogenase (LDH), and C-reactive protein (CRP) were assessed at diagnosis of BM in a discovery cohort of 1200 cancer patients. A multivariable Cox regression model was used to derive the LabBM score. The LabBM score was externally validated in an independent cohort consisting of 366 patients.Hemoglobin below lower limit of normal (<LLN; hazard ratio [HR] 1.28; P = .001), platelet count <LLN (HR: 1.36; P = .013), albumin <LLN (HR: 1.19; P = .038), LDH above upper limit of normal (>ULN; HR: 1.51; P < .001), and CRP >ULN (HR: 1.52; P < .001) were associated with survival in a multivariable Cox regression model and were included in the calculation of the LabBM score. Multivariable analysis including the LabBM score and graded prognostic assessment class revealed an independent and significant association of the LabBM score with overall survival (OS) (HR: 1.42; 95
LB  - PUB:(DE-HGF)16
C6  - pmid:28096493
C2  - pmc:PMC5570252
DO  - DOI:10.1093/neuonc/now290
UR  - https://inrepo02.dkfz.de/record/127997
ER  -